STOCK TITAN

Catalyst Pharmaceuticals Inc - CPRX STOCK NEWS

Welcome to our dedicated news page for Catalyst Pharmaceuticals (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalyst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalyst Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.35%
Tags
acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.34%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
fda approval
Catalyst Pharmaceuticals Inc

Nasdaq:CPRX

CPRX Rankings

CPRX Stock Data

1.88B
101.36M
6.41%
73.45%
4.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Coral Gables

About CPRX

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso